• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » InVivo Therapeutics opens first U.K. INSPIRE Study site

InVivo Therapeutics opens first U.K. INSPIRE Study site

July 11, 2017
CenterWatch Staff

InVivo Therapeutics announced that James Cook University Hospital in Middlesbrough, United Kingdom, has been added as the U.K.’s first clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The Golden Jubilee Regional Spinal Cord Injuries Centre located at the James Cook University Hospital, a major trauma center, focuses exclusively on patients with spinal cord injuries and is one of eight specialist centers within England.

“I am enthusiastic about the opportunity to be joining the INSPIRE study and I look forward to helping InVivo evaluate this exciting experimental technology while bringing awareness of the study to the United Kingdom,” Dr. Prasad said.

Mark Perrin, InVivo’s CEO and chairman, said, “We are thrilled to open our first INSPIRE site in the United Kingdom and are looking forward to working with Dr. Prasad and the staff at James Cook University Hospital. The INSPIRE Study is now open for enrollment across three countries: the United States, Canada and the United Kingdom.”

There are now 33 clinical sites participating in the clinical study:

  • Allegheny General Hospital, Pittsburgh, PA
  • Banner University Medical Center, Tucson, AZ
  • Barnes-Jewish Hospital at Washington University Medical Center, St. Louis, MO
  • Barrow Neurological Institute – St. Joseph’s Hospital and Medical Center, Phoenix, AZ
  • Ben Taub Hospital/Baylor College of Medicine, Houston, TX
  • Beth Israel Deaconess Medical Center, Boston, MA
  • Brigham and Women’s Hospital, Boston, MA
  • Carolina Neurosurgery and Spine Associates/Carolinas Rehabilitation, Charlotte, NC
  • Cooper Neurological Institute, Camden, NJ
  • Foothills Medical Centre, Calgary, Alberta, Canada
  • Goodman Campbell Brain and Spine/Indiana University Health Neuroscience Center, Indianapolis, IN
  • Hospital of the University of Pennsylvania, Philadelphia, PA
  • James Cook University Hospital, Middlesbrough, UK
  • Keck Hospital of University of Southern California, Los Angeles, CA
  • Medical College of Wisconsin/Froedtert Hospital, Milwaukee, WI
  • Mount Sinai Hospital, New York, NY
  • Northwestern Medicine, Chicago, IL
  • Oregon Health & Science University, Portland, OR
  • Rhode Island Hospital, Providence, RI
  • Rutgers New Jersey Medical School, Newark, NJ
  • Michael’s Hospital, Toronto, Ontario, Canada
  • Thomas Jefferson University Hospital, Philadelphia, PA
  • Toronto Western Hospital, Toronto, ON, Canada
  • UC Health Memorial Hospital, Colorado Springs, CO
  • University of California, Davis Medical Center, Sacramento, CA
  • University of California, San Diego Medical Center, San Diego, CA
  • University of Iowa Hospitals and Clinics, Iowa City, IA
  • University of Kansas Medical Center, Kansas City, KS
  • University of Louisville Hospital, Louisville, KY
  • University of New Mexico Hospital, Albuquerque, NM
  • University of Pittsburgh Medical Center Presbyterian, Pittsburgh, PA
  • University of Virginia Health System, Charlottesville, VA
  • Vidant Medical Center, Greenville, NC

The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury, is designed to demonstrate the safety and probable benefit of the Neuro-Spinal Scaffold for the treatment of complete T2-T12/L1 spinal cord injury in support of a Humanitarian Device Exemption (HDE) application for approval.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing